Mavoglurant was under
development by
Novartis and reached phase II and phase III clinical trials.[2][6] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014.[7] Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of
fragile X syndrome.[8] Mavoglurant was also in phase II clinical trials for
Levodopa-induced dyskinesia.[9][10] In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.[11] Novartis was conducting a clinical trial with this drug on
obsessive–compulsive disorder.[12]
Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.[7] Development was discontinued for other indications by 2017.[1]
Recently, Stalicla, a biotech company applying artificial intelligence to identify subgroups of high-responder patients, acquired worldwide rights from Novartis to progress the drug for substance-use and neurodevelopmental disorders.[13][14][15]
^Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, et al. (June 2011). "AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome". Neurobiology of Disease. 42 (3): 311–317.
doi:
10.1016/j.nbd.2011.01.022.
PMID21316452.
S2CID45389434.
^Witkin JM, Pandey KP, Smith JL (September 2022). "Clinical investigations of compounds targeting metabotropic glutamate receptors". Pharmacology, Biochemistry, and Behavior. 219: 173446.
doi:
10.1016/j.pbb.2022.173446.
PMID35987339.
S2CID251600367.
^Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. (January 2011). "Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056". Science Translational Medicine. 3 (64): 64ra1.
doi:
10.1126/scitranslmed.3001708.
PMID21209411.
S2CID206677267.
^Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C (Sep 2013). "Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients". The International Journal of Neuroscience. 126 (1): 20–24.
doi:
10.3109/00207454.2013.841685.
PMID24007304.
S2CID7531940.